Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10 mg kg(−1) bevacizumab biweekly and 50 mg m(−...

Descripción completa

Detalles Bibliográficos
Autores principales: Reardon, D A, Desjardins, A, Vredenburgh, J J, Gururangan, S, Sampson, J H, Sathornsumetee, S, McLendon, R E, Herndon, J E, Marcello, J E, Norfleet, J, Friedman, A H, Bigner, D D, Friedman, H S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795427/
https://www.ncbi.nlm.nih.gov/pubmed/19920819
http://dx.doi.org/10.1038/sj.bjc.6605412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795427/
https://www.ncbi.nlm.nih.gov/pubmed/19920819
http://dx.doi.org/10.1038/sj.bjc.6605412

Ejemplares similares